

ALZHEIMER'S PREVENTION & TREATMENT

| SPONSOR and PROTOCOL   | PHASE | INDICATION<br>(study population)                             | AGE     | MMSE  | DRUG/MECHANISM OF<br>ACTION                                      | CATEGORY                |
|--|-------|--|---------|-------|--|-------------------------|
| <b>Novartis/API API015A2201J (GENERATION)</b><br><a href="http://www.generationstudy.com/">http://www.generationstudy.com/</a>                               | 2/3   | At-risk<br>Homozygous<br>ApoE4                               | 60-75   | ≥24   | CAD106<br>(Anti-A-beta vaccine);<br>CNP520<br>(BACE 1 inhibitor) | Primary<br>Prevention   |
| <b>Janssen 54861911ALZ2003 (EARLY)</b><br><a href="http://clinicaltrials.gov/ct2/show/NCT02569398">http://clinicaltrials.gov/ct2/show/NCT02569398</a>        | 2b/3  | Preclinical AD   | 60 - 85 | -     | JNJ-54861911<br>(BACE 1 Inhibitor)                               | Secondary<br>Prevention |
| <b>Biogen 221AD301 (ENGAGE)</b><br><a href="http://www.engageandemerge.com/en-us/our-studies.html">http://www.engageandemerge.com/en-us/our-studies.html</a> | 3     | Mild Cognitive<br>Impairment &<br>Mild dementia due<br>to AD | 50-85   | 24-30 | Aducanumab<br>(Anti A-beta MAB)                                  | Disease<br>modifying    |
| <b>Abbvie M15-566</b><br><a href="https://clinicaltrials.gov/ct2/show/NCT02880956">https://clinicaltrials.gov/ct2/show/NCT02880956</a>                       | 2     | Mild Cognitive<br>Impairment &<br>Probable AD                | 55 - 85 | 22-30 | ABBV-8E12<br>(anti-tau monoclonal<br>antibody)                   | Disease<br>modifying    |
| <b>Eli Lilly I8D-MC-AZET (DAYBREAK-ALZ)</b><br><a href="http://autocruitment.com/daybreak-alz-study/">http://autocruitment.com/daybreak-alz-study/</a>       | 3     | Mild dementia due<br>to AD                                   | 55-85   | 20-26 | AZD3293/LY3314814<br>(BACE 1 Inhibitor)                          | Disease<br>modifying    |